🇺🇸 FDA
Patent

US 8143218

Treatment of skin, and wound repair, with thymosin beta 4

granted A61KA61K38/08A61K38/1841

Quick answer

US patent 8143218 (Treatment of skin, and wound repair, with thymosin beta 4) held by REGENERX BIOPHARMACEUTICALS, INC. expires Mon Mar 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERX BIOPHARMACEUTICALS, INC.
Grant date
Tue Mar 27 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K38/08, A61K38/1841, A61K38/2292, A61K45/06